Vancomycin with piperacillin-tazobactam is used as empirical therapy for critically ill patients. Studies of this combination against methicillin-resistant
M
ethicillin-resistant Staphylococcus aureus (MRSA) is targeted as part of empirical, broad-spectrum antibiotic therapy for patients in septic shock after blood cultures are obtained, as Ͼ60% of S. aureus infections in intensive care units in the United States are methicillin resistant (1, 2) . For over 5 decades, the mainstay of MRSA treatment has been vancomycin (VAN) (3) . In addition to VAN, it is recommended that patients who meet sepsis criteria be treated with an antipseudomonal ␤-lactam such as cefepime, an antipseudomonal ␤-lactam-␤-lactamase inhibitor combination such as piperacillin-tazobactam (TZP), or an antipseudomonal carbapenem to cover for Gram-negative pathogens (2) . Even with widespread clinical use of these regimens, little is known about how broad-spectrum ␤-lactams and VAN act in combination against MRSA. This is despite the well-documented decreased susceptibility of S. aureus to VAN and the positive correlation between S. aureus VAN susceptibility and patient outcomes (4) (5) (6) (7) (8) (9) (10) . VAN treatment has also been associated with high clinical failure rates in patients with MRSA isolates susceptible to VAN (11, 12) . Additionally, the incidence of vancomycin-intermediate S. aureus (VISA) is increasing, and VISA is also associated with treatment failures (13, 14) . While novel treatment regimens for MRSA and VISA are needed, there are few drugs in development with antimicrobial activity against MRSA and VISA. As such, investigators have begun to examine combination antibiotic therapy as a possible treatment modality for MRSA infections.
Previous in vitro studies have examined the effects of antistaphylococcal ␤-lactam (ASBL) antibiotics on VAN antimicrobial activity against MRSA and VISA isolates (15) (16) (17) (18) (19) (20) (21) . Those studies showed that the activity of VAN against MRSA is enhanced by the addition of ASBLs but did not elucidate a mechanism to explain the synergistic interaction between these ASBLs and VAN against MRSA. Nafcillin (NAF), cefazolin, cefepime, and ceftaroline have all been studied in combination with VAN against MRSA and VISA in vitro using time-kill studies and/or pharmacokinetic/ pharmacodynamic (PK/PD) models. However, the empirical clinical use of these ASBLs with VAN is low. TZP has also been studied in combination with VAN in vitro, but these data are limited to a disk diffusion study, a checkerboard analysis, and one time-kill study involving only three MRSA isolates (15) (16) (17) . Given the limited data surrounding the effects of VAN in combination with TZP, the widespread clinical use of VAN and TZP in combination, and the enhanced antimicrobial activity of VAN in combination with other ASBLs against MRSA and VISA, it is reasonable to study further the impact of TZP on VAN antimicrobial activity against MRSA and VISA. Moreover, it is imperative to compare any effect observed with that of another ASBL-VAN combination that has been shown to be effective against MRSA and VISA in vitro, such as NAF and VAN (17, 18, 21) . The primary objective of this study was to better understand the impact of TZP and NAF on VAN antimicrobial activity against MRSA and VISA. In order to meet this objective, the following outcomes were studied, with oxacillin (OXA) serving as a marker of NAF activity: (i) the antimicrobial activity of VAN in combination with TZP or OXA against clinical MRSA and VISA isolates using disk diffusion studies, (ii) the effect of VAN on the TZP and OXA MIC values for MRSA and VISA using the Etest methodology, and (iii) the effect of VAN in combination with TZP or OXA against clinical MRSA and VISA isolates in vitro using 24-h time-kill studies.
(A portion of this research was presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2012 [22] .) Disk diffusion and Etest studies. MHA plates with or without VAN at one-half the MIC of the organism were used to examine the effects of TZP or OXA with VAN against all 20 MRSA strains and all 4 VISA strains using currently recommended Clinical and Laboratory Standards Institute disk diffusion methods (23) . Strains were tested in duplicate to ensure reproducibility. A 0.5 McFarland suspension obtained from a culture grown overnight was used to inoculate MHA plates with and without VAN. Disks impregnated with OXA (1 mg/liter) or TZP (100/10 mg/liter) were placed on top of the MHA plates with and without VAN at one-half the MIC. Each plate was incubated at 37°C, and the zones of inhibition were measured after 24 h of incubation for MRSA isolates and after 24 to 48 h for VISA isolates. Additionally, for each isolate, TZP and OXA MICs were determined by using Etest methodology, as recommended by the manufacturer, in the presence or absence of VAN in the agar at one-half the MIC (24) . VAN MICs were also determined by using Etest methodology in the presence or absence of either OXA or TZP in the agar at one-half the MIC (24) . For Etest studies, plates were incubated at 37°C for 24 h; a 48-h incubation period was used for all VISA isolates to ensure adequate bacterial growth. The MIC 50 and MIC 90 were determined for all drugs alone and in combination.
MATERIALS AND METHODS
Time-kill studies. Fourteen representative MRSA isolates selected based on susceptibility results and USA type as well as the four VISA isolates were tested in time-kill experiments. All time-kill experiments were performed in test tubes with 8 ml SMHB placed on a rotator in an incubator at 37°C for 24 h. An initial inoculum of 10 6 CFU/ml was tested for all isolates. VAN at one-half the MIC for the organism, TZP (300/35 mg/liter to represent nosocomial dosing), and OXA (40 mg/liter) were tested alone and in the following combinations: TZP with VAN and OXA with VAN. Tubes containing no antibiotic were used for growth control. All time-kill experiments were conducted in duplicate. Samples were collected at 0, 2, 4, 8, and 24 h and then serially diluted in normal saline, plated in triplicate onto MHA plates, and incubated for 24 h at 37°C; a 48-h incubation period was used for VISA isolates. Colony counts were determined by visual inspection to determine log 10 CFU/ml; the lower limit of reliable detection using these methods is 2.0 log 10 CFU/ml. The mean log 10 CFU/ml reductions were compared at all time points for all antibiotic regimens tested. Synergy between VAN and TZP or OXA was defined as follows, using log 10 CFU/ml at 24 h: synergy was Ͼ2-log kill, additivity was Ͼ1-to 2-log kill, indifference was 1-log kill to 2-log growth, and antagonism was Ͼ2-log growth compared to the most active drug alone. Bactericidal activity was defined as a Ն3-log 10 CFU/ml kill at 24 h from baseline (25) .
Statistical analysis. MRSA and VISA disk diffusion results as well as VISA Etest results were described by using means and standard deviations. t tests were used to compare the means. MRSA Etest results were described by using medians and interquartile ranges (IQRs) and compared by using Wilcoxon signed-rank tests. For MRSA time-kill studies, the reduction in inoculum sizes (log 10 CFU/ml) at 24 h were compared by a one-way analysis of variance (ANOVA) using Tukey's post hoc tests for multiple comparisons of significance. For VISA time-kill studies, the 24-h reductions in inoculum size (log 10 CFU/ml) were compared by using means and standard deviations. Time to achieve 99.9% killing was determined by visual inspection of the log-linear phase of the log 10 CFU/ml-versus-time plot. All tests of significance were two tailed, and a P value of Ͻ0.05 was considered statistically significant. Statistical analyses were performed by using Sigma Plot version 11.0 (Systat Software Inc., San Jose, CA) and the Statistical Package for the Social Sciences version 20.0 (SPSS Inc., Chicago, IL). TZP MIC with the addition of VAN is shown in Fig. 1 Table 3 .
RESULTS

Bacterial
(ii) VISA isolates (n ‫؍‬ 4). For OXA and TZP, the mean zone of inhibition increased significantly with the addition of VAN at onehalf the MIC (P Ͻ 0.001 for TZP and P ϭ 0.007 for OXA). These mean zones of inhibition for each antibiotic or combination are shown in Table 1 . The mean OXA MIC decreased from 139 Ϯ 135.4 to 0.14 Ϯ 0.14 mg/liter with the addition of VAN at one-half the MIC (P ϭ 0.132). The mean TZP MIC decreased from 121 Ϯ 121.9 to 0.04 Ϯ 0.05 mg/liter with VAN at one-half the MIC (P ϭ 0.141). The mean VAN MIC determined by Etest decreased from 4 Ϯ 0 to 0.64 Ϯ 0.42 mg/liter and 0.75 Ϯ 0 mg/liter with the addition of OXA and TZP at one-half the MIC, respectively (P ϭ 0.001 for OXA).
Time-kill studies. (i) MRSA isolates (n ‫؍‬ 14). The mean log 10 CFU/ml reductions in inoculum size at 24 h and standard deviations for each antibiotic or antibiotic combination are shown in Table 4 , and a representative time-kill curve is shown in Fig. 2 . There was a statistically significant difference in the reduction of the inoculum size at 24 h depending on antibiotic exposure [F(5) ϭ 88.832; P Ͻ 0.001]. The mean 24-h reduction in inoculum for VAN with TZP was significantly greater than that for VAN or OXA alone (P Ͻ 0.001 for both) but not for TZP alone (P ϭ 0.999). The mean 24-h reduction in inoculum for OXA with VAN was also significantly greater than that for VAN or OXA alone (P Ͻ 0.001 for both) but not for TZP alone (P ϭ 0.335). VAN with TZP had a greater reduction in inoculum at 24 h than did OXA with VAN, but the difference was not statistically significant (P ϭ 0.170). VAN did not decrease the inoculum against any isolate tested. VAN with TZP was bactericidal against all isolates tested, with a mean time to bactericidal activity of 8.9 Ϯ 6.7 h. VAN with OXA was bactericidal against half of the clinical isolates tested and demonstrated synergy compared to OXA alone in 9/14 isolates tested, additivity in 4/14 isolates tested, and indifference in 1 isolate tested. The mean time to bactericidal activity for VAN with OXA was 19.4 Ϯ 7.8 h. No antagonism was observed between either antibiotic combination.
(ii) VISA isolates (n ‫؍‬ 4). The mean 24-h reductions in inoculum size for each antibiotic and combination are shown in Table  4 , and a representative time-kill curve is shown in Fig. 2 . The mean 24-h reductions in inoculum for TZP and VAN with TZP were greater than that for OXA alone but less than that for VAN with OXA. VAN with TZP demonstrated bactericidal activity against two isolates, and against one other isolate, it achieved bactericidal activity at 4 h but then experienced regrowth from 2.0 log 10 CFU/ml to 2.8 log 10 CFU/ml at 8 and 24 h. OXA with VAN demonstrated synergy compared to OXA alone and was bactericidal against all four isolates tested. No antagonism was observed between either antibiotic combination against the VISA isolates.
DISCUSSION
The results of this study show that, regardless of the in vitro methodology used, VAN with TZP or OXA has great potential for added activity against MRSA and VISA. Previous studies have found synergy with ASBLs in combination with VAN against MRSA and VISA, and our study substantiates those findings (15) (16) (17) (18) (19) (20) (21) . However, previous studies using TZP in combination with VAN were limited in scope and by the number of isolates tested (15) (16) (17) . Our study is comprehensive in terms of the number of isolates tested and the number of in vitro tests used, but it is also the first study to test VAN in combination with TZP against VISA.
Rochon-Edouard and colleagues tested VAN in combination with TZP using disk diffusion methodology and found a positive antibacterial effect against 16/32 MRSA isolates tested (15) . We utilized their methodology against 20 MRSA isolates and found that the TZP zone of inhibition for all isolates tested significantly increased with subinhibitory VAN concentrations in the agar. VAN with TZP or NAF has also shown synergistic activity against 3 MRSA isolates in 48-h time-kill studies with infected fibrin clots (17) . We tested 14 MRSA isolates in 24-h time-kill studies using the same concentrations of VAN, TZP, and OXA and found similar results. In time-kill experiments, VAN with TZP decreased the inoculum against all isolates tested. VAN with OXA decreased the inoculum against many isolates tested and showed synergistic activity against the majority of MRSA isolates and all VISA isolates tested. This confirms the synergy between VAN and OXA against MRSA and VISA demonstrated by Leonard and by Werth et al. (18, 21) . Our study is the first to demonstrate synergistic activity of VAN with TZP against VISA. While our results show that there is a synergistic effect between VAN and TZP or OXA, proposed mechanisms to understand the interaction between ASBLs and VAN against MRSA and VISA are not clearly elucidated. TZP and OXA may provoke some alteration in the MRSA cell wall that allows for improved VAN activity even if the MRSA strain is susceptible to VAN. Werth and colleagues recently described synergy between VAN and ceftaroline or OXA against VISA and heterogeneous VISA (hVISA) isolates, despite ␤-lactam exposure reducing overall VAN-Bodipy binding by approximately 50% (21) . Those authors hypothesized that beta-lactam exposure may have improved vancomycin interactions with the cell wall. Given these results and the marked decrease in VAN MICs against MRSA and VISA with the addition of subinhibitory OXA and TZP concentrations observed in our study, this is a reasonable explanation of the synergy between ASBLs and VAN. Some VISA isolates have also demonstrated an increased susceptibility to ␤-lactams in the face of rising VAN and daptomycin MICs, the "seesaw effect" (26) . While none of the VISA isolates tested in our study were determined to be susceptible to OXA or TZP, both ASBLs in combination with VAN demonstrated enhanced antibacterial activity against VISA compared to either antibiotic alone as well as VAN alone in all studies. These findings suggest that the seesaw effect may have contributed to the enhanced antibacterial activity observed with both antibiotic combinations against the VISA isolates. An alternative explanation of the synergistic activity between VAN and TZP or OXA may be that VAN alters the composition of the MRSA cell wall, allowing increased TZP and OXA binding. This mechanism may be a more plausible explanation for the results of our study, given that a subinhibitory VAN concentration was used for all experiments. In Etest studies, VAN at subinhibitory concentrations was shown to decrease all TZP and almost all OXA MICs to values less than or equal to their current susceptibility breakpoints for S. aureus. Inhibition of MRSA peptidoglycan synthesis by VAN has been shown to decrease methicillin resistance and cause MRSA to change from a homogeneous methicillin-resistant phenotype to a The current study is not the first to mention the antimicrobial effects of an ASBL with VAN against MRSA or VISA, but it is the first to mention such effects of VAN with TZP against MRSA using numerous MRSA isolates. It is also the first study to mention such an effect of VAN and TZP against VISA. When considering the results of the current study in broader contexts, it is important to note that peak TZP concentrations were used for all time-kill studies. A previous time-kill study by Palmer and Rybak using TZP at 300/35 mg/liter against MRSA led to the use of this TZP concentration in the current study (17) . Future studies using in vitro PK/PD models that simulate in vivo antibiotic exposure of both antibiotics against MRSA and VISA would further enhance our understanding of VAN-ASBL combination therapy. More indepth analyses of the manner in which TZP and VAN interact with MRSA and VISA cell walls are needed as well.
In conclusion, with the incidence of MRSA and VISA infections on the rise coupled with their high rate of treatment failures, investigators and clinicians are searching for novel treatment options for these life-threatening infections, including combination antibiotic therapy. In this study, increased antimicrobial activity against MRSA and VISA was observed when TZP or OXA was combined with subinhibitory concentrations of VAN in vitro. VAN with TZP is used often clinically, and we must be cognizant of the potential beneficial effect of VAN with TZP against S. aureus. Given the rising number of MRSA and VISA treatment failures, it is prudent to investigate the clinical effect of this antibiotic combination for the treatment of invasive MRSA and VISA infections.
